FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/083537 [Registered on: 26/03/2025] Trial Registered Prospectively
Last Modified On: 24/03/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Biological
Stem Cell Therapy
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   To compare the efficacy of platelet-rich plasma versus bone marrow-stem cell instillation in infertile women with decreased ovarian reserve undergoing IVF/ICSI treatment 
Scientific Title of Study   An open labelled, three armed, randomised placebo controlled trial to study the effect of intra-ovarian platelet-rich plasma versus autologous adult bone marrow- derived stem cell instillation in poor ovarian responders 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Neena Malhotra 
Designation  Professor and HOD, Guide 
Affiliation  All India Institute of Medical Sciences, New Delhi 
Address  701, 7th floor, Mother and Child block, All India Institute of Medical Sciences

New Delhi
DELHI
110029
India 
Phone  9891557707  
Fax    
Email  malhotraneena@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Neena Malhotra 
Designation  Professor and HOD, Guide 
Affiliation  All India Institute of Medical Sciences, New Delhi 
Address  701, 7th floor, Mother and Child block, All India Institute of Medical Sciences

New Delhi
DELHI
110029
India 
Phone  9891557707  
Fax    
Email  malhotraneena@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Dr Gunupuru Gayatri Swetha 
Designation  DM resident, Reproductive Medicine 
Affiliation  All India Institute of Medical Sciences, New Delhi 
Address  Room no 809, Hostel 19, Masjid moth doctor residential campus, AIIMS

New Delhi
DELHI
110049
India 
Phone  9966526236  
Fax    
Email  gayatriswethagunupuru@gmail.com  
 
Source of Monetary or Material Support  
All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India, 110029 
 
Primary Sponsor  
Name  AIIMS New Delhi 
Address  All India Institute of Medical Sciences, Ansari nagar East, Sir Aurobindo Marg, New Delhi, India, 110029 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Neena Malhotra  All India Institute of Medical sciences  701, 7th floor, Mother and Child block, All India Institute of Medical Sciences
New Delhi
DELHI 
9891557707

malhotraneena@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute ethics committee for post graduate research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: N979||Female infertility, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Intra-ovarian saline  2ml of normal saline injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle 
Intervention  Intraovarian autologous adult bone-marrow derived stem-cell  2ml of autologous adult bone-marrow derived stemcell injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle 
Intervention  Intraovarian Platelet rich plasma  2ml of Platelet rich plasma injected sub-cortically using a 35cm 17G single- lumen ovum pick-up needle with transvaginal ultrasound guidance under general anaesthesia once between day 6 to day 10 during one month of menstrual cycle 
 
Inclusion Criteria  
Age From  21.00 Year(s)
Age To  45.00 Year(s)
Gender  Female 
Details  1. Poor responder
a. POSEIDON group 3 and 4
(Patient-Oriented Strategy Encompassing IndividualizeD Oocyte Number)
The expected poor responder of any age group with poor ovarian reserve parameters (AFC less than 5 and/or AMH less than 1.2ng/ml) OR
b. Poor ovarian responder: less than or equal to 3 oocytes retrieved in previous IVF cycles
2. Age: 21-45 years old
3. BMI: 18-35 kg/m2
4. Willing to give consent 
 
ExclusionCriteria 
Details  1.Patients with POI, Secondary ovarian failure (e. g., hypothalamic causes, chemotherapy, radiotherapy)
2. FSH more than 12 IU/ml
3. Chronic autoimmune diseases
4. Those with major medical problems such as malignancy, hepatitis
5. Known abnormal karyotyping
6. Ovarian Endometriosis (endometrioma)
7. Prior ovarian surgery
8. Active viral infections
9. Hematologic disorders, haemoglobin level of less than 11.0 g/dL or platelet count of less than 150,000/ul 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1.Number of oocytes retrieved
2.Number of mature oocytes (MII) retrieved 
In one IVF cycle, 3 months after the intervention 
 
Secondary Outcome  
Outcome  TimePoints 
1. FSH, AMH levels
2. Antral Follicle Count, Ovarian volume
3. Dose of gonadotropins
4. Duration of gonadotropin stimulation
5. Level of E2 on the day of trigger
6. Fertilization rate
7. Cleavage rate
8. Blastulation rate
9. Number of good quality embryos
10. Cycle cancellation rate
11. Clinical pregnancy rate per embryo transfer
12. Cumulative clinical pregnancy rate
13. Safety outcomes (post-procedure)
a. pain
b. bleeding
c. abscess or infection
d. injury to any vital organs
e. allergic reactions
f. anaesthesia- related complications. 
In one IVF cycle, 3 months after the intervention 
 
Target Sample Size   Total Sample Size="39"
Sample Size from India="39" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/04/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Poor ovarian response (POR) to gonadotropin stimulation in an IVF cycle remains one of the challenges faced by infertility experts, world-wide. In the recent years, the numbers of poor ovarian responders, both expected, as well as unexpected, are on the rise. Despite better understanding of Controlled ovarian stimulation (COS), and recent advances in laboratory techniques, the estimated prevalence of poor responders, according to the POSEIDON criteria, is around 40%. Various strategies have been developed to help these couples produce their own genetic offspring, helping women through better regimens for pituitary suppression, increased gonadotropin dosages and the addition of adjuvant agents during ovarian stimulation however, high-level evidence on the ideal protocol or strategies using uniform standards for POR are lackingTherefore, in pursuit of other effective strategies, the role of intraovarian platelet rich plasma (PRP) and intraovarian stem cell instillation are being extensively studied over the last few years. 

Autologous platelets are believed to promote the development of isolated human primordial and primary follicles to the pre-antral stage, reduce follicular atresia, restore dormant oocytes, thereby restoring fertility. Although there are currently multiple methods for preparing and injecting PRP, there is still no consensus on the optimal method, and there is still controversy over whether ovarian injection of PRP can improve ovarian function. A few case reports, retrospective and prospective cohort, non-randomised studies suggest that PRP treatment may benefit women with poor ovarian response. But, a couple of RCTs have not shown any significant effect of PRP on the oocyte yield. In a recently published RCT conducted by Barrenetxea et al.,(2024), an increase in the number of retrieved oocytes in both the intraovarian PRP group and intraovarian saline group suggests that, beyond the release of growth factor from platelets, a mechanical effect can play a role. They hypothesised that either delivered platelet factors or a potential mechanical effect could be implicated in promoting follicle reactivation. 

Stem Cells derived from different sources may have some effect on the rescue of ovary function, such as recovering ovarian sex hormone function, reducing apoptosis of germ cells, and increasing the number of follicles. However, the improved ovarian function after stem-cell transplantation is a complex mix of many unclear factors requiring further investigation including their activation by mechanical stimulation. Recent studies have shown contradictory results in terms of its efficacy. Considering the complexity of an autologous product such as PRP or stem-cell and the need for quality control in clinical applications, the ability to reproduce consistent results must be shown before recommending them in clinical practice. Given this context, to strengthen the evidence in the form of randomised controlled trial, our research question aims to determine whether instilling intraovarian PRP or stem cells or saline leads to improvements in ovarian reserve and IVF outcomes. If found useful, they would signify a paradigm shift in fertility treatment for women with POR. 

 

 
Close